SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).

Trial Profile

SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs ATX MS 1467 (Primary) ; ATX MS 1467 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Apitope Technology
  • Most Recent Events

    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 03 Sep 2013 Results have been reported in an Apitope media release. New Gd and total Gd enhancing lesions, on MRI, were decreased with intradermal ATX-MS-1467 but not with subcutaneous ATX-MS-1467.
    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top